Market Structure for essential medicines
Kestrian is building a new infrastructure layer for the global generics market — focused on continuity and resilience
Independent by design
Kestrian never trades, brokers, holds inventory or takes title in any medicine it assesses. An institution whose assessments are relied on cannot also be a counterparty. That rule is permanent and it is stated on every page we publish.
Built from the public record
Marketing authorisations, framework awards, transacted hospital prices and supply notifications are published by regulators and health services, in scattered places and formats that overwrite themselves. Kestrian archives them as they appear, joins them at the level of the individual presentation, and keeps every record as it stood on the day it was captured.
Single author
Kestrian’s methodology, corrections policy and every published note are written and signed by Jamie Coleman. Each figure links to the document it came from. Corrections are published, dated and never overwritten.
Who it is for
Manufacturers deciding which lines to tender, investors and advisers assessing a generics business, and the public bodies that procure and stockpile essential medicines. The first edition covers UK hospital generics at line level.